Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...

Moderna (NasdaqGS:MRNA) reported positive Phase 3 clinical data for its investigational influenza vaccine mRNA-1010 and RSV ...

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it ...

Political interference is driving biotech investment overseas, and U.S. patients and workers will pay the price.

Moderna, Inc. (NASDAQ:MRNA) is among the stocks in focus as Jim Cramer reviewed the S&P 500’s top performers and the Nasdaq 100’s biggest laggards for the first quarter. Cramer highlighted the bullish ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna's headquarters in Cambridge, Mass., in 2024. (dam Glanzman / Bloomberg via Getty Images) (Adam Glanzman) The Food and Drug ...

Broader biotech positioning aligns with movements tracked across the nasdaq ecosystem.

Moderna's full pipeline may fuel long-term growth.

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The news is the ...

The U.S. Food and Drug Administration (FDA) refused to consider Moderna’s application for a new flu vaccine using mRNA technology, the company announced Tuesday, a decision that could delay the ...